The development of bone substitute materials containing therapeutically active agents is an attractive and useful tool for treating bone loss and inflammation associated with musculoskeletal diseases. In this context, calcium phosphate-based materials, including cements widely used to repair bone tissue, can also be a valuable carrier for local drug delivery. However, poor mechanical properties limit their load-bearing applications. In this work, the effects of incorporation of (1) a small amount of chitosan (CH) in the absence and presence of genipin (G) and (2) a diclofenac mass fraction of 2.5 wt% (DCF, a non-steroidal anti-inflammatory drug) in α-TCP-based apatite cement composition with a liquid-to-powder mass ratio (LPR) of 0.33 were investigated. For this purpose, compressive strength, phase composition, microstructure, porosity, pore-size distribution, the DCF distribution throughout the cement, and in vitro DCF release profiles and kinetics at two different pH values (7.4 and 5.5) were evaluated. The addition of CH/G increased the compressive strength from 40 ± 5 to 58 ± 7 MPa. The presence of DCF together with these additives slightly decreased the compressive strength value to 54 ± 4 MPa. The amount of DCF released after 21 days at pH 7.4 decreases from 34.6 ± 3.7 % to 19.1 ± 2.7 % for the calcium phosphate cement matrix in the absence and presence of the CH/G, respectively. The formulations containing CH/G and CH/G/DCF were selected for further study of the effects of LPR increase (0.40 and 0.45) under the same conditions. The results indicated that the presence of CH/G in α-TCP-based apatite cement mainly changes the porosity, pore size distribution and the phases formed in the setting reaction, which in turn affect the mechanical properties and the drug release profiles.
Author Contributions
Conceptualization: P.M.C.T., A.F.B. and L.G.; methodology: M.A.M., J.O., P.Z., L.M., S.O., L.G., A.F.B. and P.M.C.T.; data curation: M.A.M., J.O., P.Z., L.G, A.F.B. and P.M.C.T.; resources: P.M.C.T., S.O., L.M., A.F.B. and L.G.; supervision: P.M.C.T., A.F.B., L.G.; writing—original draft preparation: P.M.C.T., A.F.B. and M.A.M.; writing—review and editing: P.M.C.T., A.F.B., P.Z. and S.O.; project administration: P.M.C.T., S.O. and A.F.B.; funding acquisition: P.M.C.T., S.O., L.M., A.F.B. and L.G. All authors have read and agreed to the published version of the manuscript.
Funding
This work is funded by FEDER funds through the COMPETE 2020 Program and National Funds through FCT—Portuguese Foundation for Science and Technology under the projects FlexMicroDerm (POCI-01-0145-FEDER-029274) and 2BBone (POCI-01-0145-FEDER-029940). This work was also developed within the scope of the projects of iMed.ULisboa, UIDB/04138/2020 and UIDP/04138/2020, and CICECO-Aveiro Institute of Materials, UIDB/50011/2020, UIDP/50011/2020 & LA/P/0006/2020, financed by national funds through the FCT/MEC (PIDDAC). P. M. C. Torres, S. Olhero and L. Gonçalves acknowledge FCT for CEECIND/01891/2017 and CEECIND/03393/2017 and CEECIND/03143/2017 contracts, respectively.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The data presented in this study are available on request from the corresponding authors.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).